Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer

被引：32

作者：

Chi, Kim N. ^{[1
]}

Zoubeidi, Amina ^{[1
]}

Gleave, Martin E. ^{[1
]}

机构：

[1] Univ British Columbia, Prostate Ctr, Vancouver Gen Hosp, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 12期

关键词：

antisense oligonucleotide; cancer; clusterin; custirsen; prostate cancer;

D O I：

10.1517/13543780802528609

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA; it is currently in clinical trials for patients with cancer. Objective/methods: To review the literature on the role of clusterin in cancer progression and treatment resistance, and to summarize completed and ongoing clinical trials with custirsen. Results/conclusions: Custirsen is well tolerated in humans and biologically active in inhibiting expression of clusterin in patients with cancer. Randomized trials of custirsen in combination with chemotherapy are planned in patients with castration-resistant prostate cancer.

引用

页码：1955 / 1962

页数：8

共 41 条

[1] Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway [J].

Ammar, Hayet ;

Closset, Jean L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (19) :12851-12861

[2]

Calero M, 2005, SUB CELL BIOCHEM, V38, P273

[3] Clusterin as a therapeutic target for radiation sensitization in a lung cancer model [J].

Cao, C ;

Shinohara, ET ;

Li, HC ;

Niermann, KJ ;

Kim, KW ;

Sekhar, KR ;

Gleave, M ;

Freeman, M ;

Lu, B .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (04) :1228-1236

[4] Clusterin as a biomarker in murine and human intestinal neoplasia [J].

Chen, XD ;

Halberg, RB ;

Ehrhardt, WM ;

Torrealba, J ;

Dove, WF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) :9530-9535

[5] A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer [J].

Chi, Kim N. ;

Siu, Lillian L. ;

Hirte, Hal ;

Hotte, Sebastien J. ;

Knox, Jennifer ;

Kollmansberger, Christian ;

Gleave, Martin ;

Guns, Emma ;

Powers, Jean ;

Walsh, Wendy ;

Tu, Dongsheng ;

Eisenhauer, Elizabeth .

CLINICAL CANCER RESEARCH, 2008, 14 (03) :833-839

[6] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer [J].

Chi, KN ;

Eisenhauer, E ;

Fazli, L ;

Jones, EC ;

Goldenberg, SL ;

Powers, J ;

Tu, DS ;

Gleave, ME .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1287-1296

[7]

CHI KN, 2007, J CLIN ONCOL, V25

[8]

CHIA S, 2007, P 97 ANN M AM ASS CA

[9]

CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329

[10] Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis [J].

Dai, Chengkai ;

Whitesell, Luke ;

Rogers, Arlin B. ;

Lindquist, Susan .

CELL, 2007, 130 (06) :1005-1018

← 1 2 3 4 5 →